Clinical Quiz: Intranasal Corticosteroids in CRSwNP

Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a prevalent and often debilitating inflammatory condition, affecting approximately 2–4% of the global population. Characterized by persistent sinonasal inflammation and polyp formation, CRSwNP leads to nasal congestion, loss of smell, and significantly reduced quality of life. Management of this condition requires a combination of pharmacologic and surgical approaches, with intranasal corticosteroids (INCS) remaining the mainstay of first-line medical therapy.

The GRADE guidelines reaffirm the critical role of INCS in CRSwNP treatment, emphasizing their effectiveness in reducing polyp size, improving nasal airflow, and alleviating symptoms. Various formulations and delivery methods have been studied, and recent evidence highlights the benefits of high-volume irrigation combined with INCS for enhanced drug delivery. While INCS are generally well-tolerated, concerns regarding long-term use, patient adherence, and potential systemic absorption persist.

This quiz will test your knowledge of the evidence-based use of INCS in CRSwNP, including optimal dosing strategies, clinical outcomes, and guideline-recommended approaches for maximizing efficacy while minimizing adverse effects. How well do you understand the nuances of INCS therapy in CRSwNP? Let’s find out!

This quiz was created in part with AI based on guidelines from the reference document below.

Reference

Rank MA, Chu DK, Bognanni A, et al. The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol. 2023;151(2):386-398. doi:10.1016/j.jaci.2022.10.026